跳至主要内容
临床试验/NL-OMON48407
NL-OMON48407撤回不适用

ano-MRI to visualize pancreatic inflammation in individuals with recent-onset type 1 diabetes - Nano-PRIDE

ucleaire geneeskunde en radiologie0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Inclusion criteria (Individuals with type 1 diabetes):
  • * Within 6 months of diagnosis with type 1 diabetes
  • * Auto-antibody positive, - Inclusion criteria (Control individuals):
  • * No evidence of impaired glucose tolerance (HbA1c < 42 mmol/mol (6%),
  • fasting glucose < 6.1 mmol/L), - Inclusion criteria (general):
  • * Age > 18 years
  • Signed informed consent

排除标准

  • - Contra-indication to MRI scanning, iron infusion or hypersensitivity to the
  • active substance or any of the excipients (like mentioned in the SPC).
  • - Known drug allergies or history of severe asthma, eczema or other ectopic
  • - Inability to lie still for at least 30 minutes or comply with imaging
  • - Hemochromatosis or liver disease defined as ALAT or ASAT level of more than
  • three times the upper limit of normal range
  • - Renal dysfunction defined as MDRD < 40 ml/min/1.73m^2
  • - Current pregnancy or the wish to become pregnant within 2 months
  • - Breast feeding
  • - Incapability to provide informed consent
  • - Pancreatitis
  • - Evidence of other inflammatory disease(s)

研究者

发起方
ucleaire geneeskunde en radiologie

相似试验